Compare GMED & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GMED | NBIX |
|---|---|---|
| Founded | 2003 | 1992 |
| Country | United States | United States |
| Employees | N/A | 2000 |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9B | 13.2B |
| IPO Year | 2012 | 1996 |
| Metric | GMED | NBIX |
|---|---|---|
| Price | $87.84 | $132.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 22 |
| Target Price | $100.42 | ★ $175.27 |
| AVG Volume (30 Days) | ★ 822.9K | 810.0K |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 422.67 | 41.95 |
| EPS | 3.92 | ★ 4.67 |
| Revenue | ★ $2,938,931,000.00 | $161,626,000.00 |
| Revenue This Year | $11.13 | $22.85 |
| Revenue Next Year | $6.28 | $10.36 |
| P/E Ratio | ★ $22.00 | $28.20 |
| Revenue Growth | 16.65 | ★ 977.51 |
| 52 Week Low | $51.79 | $84.23 |
| 52 Week High | $101.40 | $160.18 |
| Indicator | GMED | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 52.92 | 54.02 |
| Support Level | $85.61 | $128.03 |
| Resistance Level | $92.48 | $136.74 |
| Average True Range (ATR) | 2.14 | 3.27 |
| MACD | 0.15 | 0.47 |
| Stochastic Oscillator | 98.34 | 80.18 |
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.